Sector News

Sage Therapeutics fuels, then dampens, its own M&A rumors

February 17, 2017
Life sciences

In an interview with Bloomberg published yesterday, Sage’s CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending its shares jumping.

But a few short hours later (and just before the end of after-hours trading), the chief rowed back on the M&A talk.

This comes as the company also got a share boost after its major depressive disorder candidate SAGE-217 recently hit its marks in a small, phase 2 test.

Bloomberg got an interview with Jonas about the data, where he said Sage was “on top of everyone’s M&A list,’’ and has been “hearing a great deal from a lot of companies,” an uncommon mantra from a biotech CEO, especially after a relatively small trial win, but with much more to be done.

But markets like these words, so cue its shares up by 9% in normal trading hours on the news. But later yesterday evening, the company released a statement trying to lower the tone of these comments.

“Dr. Jonas acknowledged the industry’s interest in the MDD data,” the brief update said. “Dr. Jonas’ statements did not imply that the company was in discussions with potential buyers […] Sage will have no further comment on these matters and as a policy does not comment on speculation regarding M&A activities.”

Its shares fell 1.2% afterhours, with its biggest dip coming after the release of this statement, and was down around 5% premarket this morning.

By Ben Adams

Source: Fierce Biotech

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend